BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
8:30 AM | Thursday | May 14, 2026 Business Wire

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

News Thumbnail
12:27 AM | Tuesday | May 12, 2026 PRNewsWire

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

News Thumbnail
6:59 AM | Friday | May 8, 2026 Business Wire

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

News Thumbnail
6:59 AM | Wednesday | May 6, 2026 Business Wire

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

News Thumbnail
6:59 AM | Monday | May 4, 2026 Business Wire

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™

News Thumbnail
6:59 AM | Thursday | Apr 30, 2026 Business Wire

Bristol Myers Squibb Reports First Quarter Financial Results for 2026

News Thumbnail
6:59 AM | Friday | Apr 24, 2026 Business Wire

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

News Thumbnail
8:00 AM | Thursday | Apr 23, 2026 PRNewsWire

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

News Thumbnail
7:00 AM | Tuesday | Apr 21, 2026 Business Wire

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion

News Thumbnail
8:00 AM | Monday | Apr 20, 2026 GlobeNewsWire

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

News Thumbnail

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Business Wire

8:30 AM | Thursday | May 14, 2026

news photo
Loading...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs. With Lens, Tempus' AI-enabled analytical pl.

Read full article redirect
8:30 AM | Thursday | May 14, 2026

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Business Wire

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs. With Lens, Tempus' AI-enabled analytical pl.

Read full article arrow
News Thumbnail
12:27 AM | Tuesday | May 12, 2026

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

PRNewsWire

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to address significant unmet patient needs and support long ‑ term growth SHANGHAI and PRINCETON, N.J., May 12, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui") (600276.SH; 01276.HK) and Bristol Myers Squibb ("BMS") today announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide.

Read full article arrow
News Thumbnail
6:59 AM | Friday | May 8, 2026

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.

Read full article arrow
News Thumbnail
6:59 AM | Wednesday | May 6, 2026

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026.

Read full article arrow
News Thumbnail
6:59 AM | Monday | May 4, 2026

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™.

Read full article arrow
News Thumbnail
6:59 AM | Thursday | Apr 30, 2026

Bristol Myers Squibb Reports First Quarter Financial Results for 2026

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2026.

Read full article arrow
News Thumbnail
6:59 AM | Friday | Apr 24, 2026

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Eliquis--Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company.

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Apr 23, 2026

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

PRNewsWire

SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.

Read full article arrow
News Thumbnail
7:00 AM | Tuesday | Apr 21, 2026

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion

Business Wire

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne®CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation Medicine's longstanding relationship in advancing biomarker-driven therapies with Br.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Apr 20, 2026

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

GlobeNewsWire

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W.

Read full article arrow
News Thumbnail